EUVIMEDEUVIMED entdecken
Crossref

Engineered Toll-like Receptor Nanoagonist Binding to Extracellular Matrix Elicits Safe and Robust Antitumor Immunity

Liu Yang, Yue Lang, Haoguang Wu, Kaiyan Xiang, Yuanzheng Wang, Mengqi Yu, Yu Liu, Bowei Yang, Liangcan He iD, Guangming Lu iD, Qianqian Ni, Xiaoyuan Chen iD und 1 weitere

ACS Nano · 2023

DOI: 10.1021/acsnano.2c08429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2023. Verfasst von Liu Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002 Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Medical Research Council, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansAnimalsMiceOligodeoxyribonucleotidesAdjuvants, ImmunologicImmunotherapyDNAToll-Like ReceptorsToll-Like Receptor 9Mice, Inbred C57BL

Stichwörter der Autor:innen

Toll-like receptorcancer immunotherapyextracellular matrixnanoagonistrolling circle amplification

Substanzen

OligodeoxyribonucleotidesAdjuvants, ImmunologicDNAToll-Like ReceptorsToll-Like Receptor 9

Autor:innen und Institutionen

  • Department of Radiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002 Jiangsu, China.
  • National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002 Jiangsu, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
  • Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
  • School of Medicine and Health, Harbin Institute of Technology, Harbin 150080, China.
  • Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.

ORCID-Profile: Liangcan He, Guangming Lu, Xiaoyuan Chen

Förderung

  • Ministry of Science and Technology of the People's Republic of China
  • National Medical Research Council
  • Natural Science Foundation of Jiangsu Province
  • National University of Singapore
  • National Natural Science Foundation of China

Zitieren

APA

Yang, L., Lang, Y., Wu, H., Xiang, K., Wang, Y., Yu, M., Liu, Y., Yang, B., He, L., Lu, G., Ni, Q., Chen, X., & Zhang, L. (2023). Engineered Toll-like Receptor Nanoagonist Binding to Extracellular Matrix Elicits Safe and Robust Antitumor Immunity. ACS Nano. https://doi.org/10.1021/acsnano.2c08429

Vancouver

Yang L, Lang Y, Wu H, Xiang K, Wang Y, Yu M, et al. Engineered Toll-like Receptor Nanoagonist Binding to Extracellular Matrix Elicits Safe and Robust Antitumor Immunity. ACS Nano. 2023. doi:10.1021/acsnano.2c08429

BibTeX
@article{Yang2023,
  author = {Yang, Liu and Lang, Yue and Wu, Haoguang and Xiang, Kaiyan and Wang, Yuanzheng and Yu, Mengqi and Liu, Yu and Yang, Bowei and He, Liangcan and Lu, Guangming and Ni, Qianqian and Chen, Xiaoyuan and Zhang, Longjiang},
  title = {Engineered Toll-like Receptor Nanoagonist Binding to Extracellular Matrix Elicits Safe and Robust Antitumor Immunity},
  journal = {ACS Nano},
  year = {2023},
  doi = {10.1021/acsnano.2c08429}
}
Kostenlos starten →